<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979663</url>
  </required_header>
  <id_info>
    <org_study_id>2021-07-2310</org_study_id>
    <nct_id>NCT04979663</nct_id>
  </id_info>
  <brief_title>GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer</brief_title>
  <official_title>Safety and Efficacy of GEMOX Combined With Donafenib and Tislelizumab as First-line Treatment in Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design: Prospective, single-arm, single-center study; Primary endpoint: Safety;&#xD;
      Secondary endpoints: Disease control rate, overall response rate, conversion rate, overall&#xD;
      survival; Main characteristics of enrolled patients: Patients with initially unresectable&#xD;
      biliary tract cancer; Interventions: Combination of Gemcitabine, Oxaliplatin, Donafenib and&#xD;
      Tislelizumab; Sample size: 10 patients;&#xD;
&#xD;
      Treatment until:&#xD;
&#xD;
        1. successfully conversed to resectable disease&#xD;
&#xD;
        2. progressed disease&#xD;
&#xD;
        3. intolerable toxicity&#xD;
&#xD;
        4. patient requests withdrawal Research process: In this study, patients who met the&#xD;
           inclusion criteria were evaluated at the end of every 2 circles of treatment (6 weeks),&#xD;
           up to surgical treatment or disease progression.&#xD;
&#xD;
      Safety evaluation: Evaluate adverse reactions according to CTCAE 4.0; Follow up: 12 months&#xD;
      after the last case was enrolled.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: the incidence of adverse events and serious adverse events</measure>
    <time_frame>3 weeks</time_frame>
    <description>Incidence of adverse events and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Conversion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 weeks</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Biliary Tract Carcinoma</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Gemox, Donafenib and Tislelizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab</intervention_name>
    <description>Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years and ≤80 years;&#xD;
&#xD;
          2. ECOG physical condition score: 0~1;&#xD;
&#xD;
          3. Histologically or cytologically confirmed malignant tumor of epithelial origin in the&#xD;
             biliary system;&#xD;
&#xD;
          4. Preoperative imaging assessment of the disease stage was III/IV;&#xD;
&#xD;
          5. The main organs function well, and the examination indicators meet the following&#xD;
             requirements:&#xD;
&#xD;
        Routine blood tests: Hemoglobin ≥90 g/L (no blood transfusion within 14 days); Neutrophil&#xD;
        count ≥1.5×10^9/L; Platelet count ≥80×10^9/L; Biochemical examination: Total bilirubin&#xD;
        ≤2×ULN (upper normal value); ALT or AST ≤ 2.5×ULN; Endogenous creatinine clearance ≥ 50 mL&#xD;
        /min (Cockcroft-Gault formula); 6. Sign the informed consent voluntarily; 9. Good&#xD;
        compliance, and family members willing to cooperate with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with other uncured malignant tumors;&#xD;
&#xD;
          2. Pregnant or lactating women who are required to withdraw from the clinical trial if&#xD;
             they become pregnant during the study period;&#xD;
&#xD;
          3. Previous antitumor therapy for the disease in this study;&#xD;
&#xD;
          4. Participated in clinical trials of other drugs within one month;&#xD;
&#xD;
          5. Patients with a known history of other systemic serious diseases before screening;&#xD;
&#xD;
          6. Long-term unhealed wounds or incomplete healing fractures;&#xD;
&#xD;
          7. Previous organ transplantation history;&#xD;
&#xD;
          8. Abnormal coagulation function;&#xD;
&#xD;
          9. Screening for overactivity/venous thrombosis events in the previous year, such as&#xD;
             cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis&#xD;
             and pulmonary embolism;&#xD;
&#xD;
         10. Having a history of abuse of psychotropic substances and being unable to quit or&#xD;
             having mental disorders;&#xD;
&#xD;
         11. A history of immune deficiency or other acquired or congenital immunodeficiency&#xD;
             diseases, or a history of organ transplantation;&#xD;
&#xD;
         12. Concomitant conditions that, in the investigator's judgment, seriously endanger the&#xD;
             patient's safety or affect the patient's completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lu Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu Wang, M.D.</last_name>
    <phone>+86-18121299357</phone>
    <email>w.lr@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu Wang, M.D.</last_name>
      <phone>+86-18121299357</phone>
      <email>w.lr@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Lu Wang, MD, PhD</investigator_full_name>
    <investigator_title>Head of liver surgery department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

